Atai Life Sciences, a biopharmaceutical company trading on the Nasdaq as ATAI, announced plans to establish a Bitcoin treasury strategy, beginning with a $5 million Bitcoin purchase. Atai, which focuses on treating mental health disorders, recognizes Bitcoin's potential as a strategic asset for treasury management, especially for biotech companies facing inflation-related risks. The firm is set to acquire approximately 59.23 BTC with its initial investment, emphasizing a cautious approach to cash reserves and operational timelines. Atai's founder, Christian Angermayer, highlighted the need for biotech firms to adapt to macroeconomic pressures and indicated plans to clarify the philosophical connections between psychedelics and Bitcoin in future communications. Despite the announcement, ATAI shares have seen a decline of more than 1% and are significantly lower than their all-time highs, reflecting market volatility and broader economic challenges.

Source 🔗